@FierceMedDev: Alere's proxy fight gets personal in latest round. More | Follow @FierceMedDev
@MarkHFierce: The clock is ticking. Send in your 2013 FMD Fierce 15 nominations. Submit now | Follow @MarkHFierce
@DamianFierce: Quest dims revenue outlook as it sells stake in J&J cancer drug. Story | Follow @DamianFierce
> Danaher ($DHR) hauled in a record $4.7 billion in the second quarter, 4% over the same period last year, and net income rose 3.5% to $616.8 million. Results
> Despite all the hand-wringing over the 2.3% excise tax, RBC Capital Markets analysts say many medical device companies will benefit once the Affordable Care Act's insurance mandates kick in next year. Report
> TB Biosciences has raised a $1.5 million Series A to develop a point-of-care diagnostic for tuberculosis. Release
> Illumina ($ILMN) has launched a phasing analysis offering for its whole-genome mapping services, allowing researchers to identify segments of connected variants within a gene. News
> In an interview with The Los Angeles Times, Ambry Genetics CEO Charles Dunlop said Myriad Genetics' ($MYGN) lawsuit against his company is without merit. "I don't know what they're doing other than just bullying people," he said. Article
> India's FDA sealed the plant of a local device manufacturer after finding that some of its orthopedic implants weren't sterile. Story
> In a study published in the Journal of the American College of Cardiology, covered stents showed better patency at 12 months than standard bare-metal implants. Item
> Diagnostics outfit Venaxis ($APPY) has notched some positive early results for the APPY1 Test, designed to gauge a patient's risk of appendicitis, and the company said it's on track to file for FDA approval. More
Biotech News
@FierceBiotech: After Eylea win, Regeneron execs puzzle over R&D scale-up challenge. Article | Follow @FierceBiotech
@JohnCFierce: Ensemble hasn't raised VC $$ since 2007--which is impressive. Funded by marquee collaborations. | Follow @JohnCFierce
@EmilyMFierce: ICYMI: NIH confirms it's shelving India drug trials in wake of new regs. Editor's corner | Follow @EmilyMFierce
> Booming Alexion looks to Ensemble platform for ultrarare disease programs. Article
> OncoMed extends the biotech IPO winning streak with $82M haul. News
Pharma News
@FiercePharma: Merck taps India's Lupin to market pneumococcal vax under new name. In U.S., brand = Pneumovax 23. More | Follow @FiercePharma
@CarlyHFierce: Vivus holding its annual meeting this morning. Stay tuned for the end of the proxy fight with First Manhattan--and its outcome. | Follow @CarlyHFierce
> Novartis under U.S. scrutiny for Gilenya marketing tactics. Story
> Deaths force Celgene to stop Revlimid CLL trial in its tracks. News
> Lilly freezes salaries ahead of patent loss for Cymbalta. Report
Pharma Manufacturing News
@EricPFierce: From FierceVaccines.com: ABC's appointment of Jenny McCarthy sparks media furor. News | Follow @EricPFierce
> UAE expects big growth in generic drug production. Item
> Penn Pharma to expand plant opened in May. Report
> China regulators pledge new crackdown on counterfeit drug operations. More
> J&J says it has upped its quality game across all 120 plants. Article
> Cispharma warning letter says injury investigation inadequate. Story
Vaccines News
> Gates-backed device extends cold chain to rural areas. Report
> Bio Farma taps Artes for VLP technology. Item
> ABC's appointment of Jenny McCarthy sparks media furor. More
> New data supports vaccinating gay men against HPV. Story
> Sanofi starts up dengue vaccine plant to maintain edge over Takeda. Article